Participated · Equity · Oct 2025

iOrganBio is a 2024-founded biotech company leveraging its proprietary CellForge™ platform to industrialize the production of human cells and organoids for drug discovery, regenerative medicine, and cell therapies. CellForge integrates AI-based predictive modeling with high-throughput, closed-loop control of 3D culture environments to optimize human pluripotent stem cell differentiation in real time. Central to the system is the Functional Human CellAtlas™, a growing single-cell multi-omics database that serves as a digital blueprint for engineering targeted cell states. Early applications include generating pancreas models with tailored vasculature and immune competency by selectively producing beta islet cells. The company addresses key industry bottlenecks—definability, generalizability, adaptability, reproducibility, and scalability—to deliver reproducible and cost-effective cell manufacturing. iOrganBio is headquartered at BioLabs in Chapel Hill, NC and currently operates with $2 million in initial capital; no revenue or user metrics were disclosed.

Participated · Series B · Aug 2025

Incyclix Bio is advancing INX-315, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, as its lead clinical compound. INX-315 is in a Phase 1/2 open-label, dose-escalation, combination and dose-expansion trial (NCT05735080) targeting advanced and metastatic breast and ovarian cancers, including CDK4/6 inhibitor resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors. The company positions itself as a scientific leader in understanding CDKs and their role in the cell cycle, and was founded by pioneers in CDK inhibitor discovery, research and development. Headquartered in Research Triangle Park, N.C., Incyclix is focusing resources on advancing INX-315 through clinical development with the recent Series B extension funding. No revenue or user metrics were disclosed in the announcement.